205 related articles for article (PubMed ID: 36163168)
1. RAS oncogenic activity predicts response to chemotherapy and outcome in lung adenocarcinoma.
East P; Kelly GP; Biswas D; Marani M; Hancock DC; Creasy T; Sachsenmeier K; Swanton C; ; Downward J; de Carné Trécesson S
Nat Commun; 2022 Sep; 13(1):5632. PubMed ID: 36163168
[TBL] [Abstract][Full Text] [Related]
2.
Skoulidis F; Goldberg ME; Greenawalt DM; Hellmann MD; Awad MM; Gainor JF; Schrock AB; Hartmaier RJ; Trabucco SE; Gay L; Ali SM; Elvin JA; Singal G; Ross JS; Fabrizio D; Szabo PM; Chang H; Sasson A; Srinivasan S; Kirov S; Szustakowski J; Vitazka P; Edwards R; Bufill JA; Sharma N; Ou SI; Peled N; Spigel DR; Rizvi H; Aguilar EJ; Carter BW; Erasmus J; Halpenny DF; Plodkowski AJ; Long NM; Nishino M; Denning WL; Galan-Cobo A; Hamdi H; Hirz T; Tong P; Wang J; Rodriguez-Canales J; Villalobos PA; Parra ER; Kalhor N; Sholl LM; Sauter JL; Jungbluth AA; Mino-Kenudson M; Azimi R; Elamin YY; Zhang J; Leonardi GC; Jiang F; Wong KK; Lee JJ; Papadimitrakopoulou VA; Wistuba II; Miller VA; Frampton GM; Wolchok JD; Shaw AT; Jänne PA; Stephens PJ; Rudin CM; Geese WJ; Albacker LA; Heymach JV
Cancer Discov; 2018 Jul; 8(7):822-835. PubMed ID: 29773717
[No Abstract] [Full Text] [Related]
3. Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification.
Elkrief A; Odintsov I; Markov V; Caeser R; Sobczuk P; Tischfield SE; Bhanot U; Vanderbilt CM; Cheng EH; Drilon A; Riely GJ; Lockwood WW; de Stanchina E; Tirunagaru VG; Doebele RC; Quintanal-Villalonga Á; Rudin CM; Somwar R; Ladanyi M
J Thorac Oncol; 2023 Sep; 18(9):1165-1183. PubMed ID: 37182602
[TBL] [Abstract][Full Text] [Related]
4. Loss of wild type KRAS in KRAS
Liu Y; Gao GF; Minna JD; Williams NS; Westover KD
Lung Cancer; 2021 Mar; 153():73-80. PubMed ID: 33465697
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience.
El Osta B; Behera M; Kim S; Berry LD; Sica G; Pillai RN; Owonikoko TK; Kris MG; Johnson BE; Kwiatkowski DJ; Sholl LM; Aisner DL; Bunn PA; Khuri FR; Ramalingam SS
J Thorac Oncol; 2019 May; 14(5):876-889. PubMed ID: 30735816
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer.
Gerber DE; Camidge DR; Morgensztern D; Cetnar J; Kelly RJ; Ramalingam SS; Spigel DR; Jeong W; Scaglioni PP; Zhang S; Li M; Weaver DT; Vaikus L; Keegan M; Horobin JC; Burns TF
Lung Cancer; 2020 Jan; 139():60-67. PubMed ID: 31739184
[TBL] [Abstract][Full Text] [Related]
7. Concomitant genomic alterations in KRAS mutant advanced lung adenocarcinoma.
Gibert J; Clavé S; Hardy-Werbin M; Taus Á; Rocha P; Longarón R; Piquer G; Chaib I; Carcereny E; Morán T; Salido M; Dalmases A; Bellosillo B; Arriola E
Lung Cancer; 2020 Feb; 140():42-45. PubMed ID: 31862576
[TBL] [Abstract][Full Text] [Related]
8. SMARCA4 mutations in KRAS-mutant lung adenocarcinoma: a multi-cohort analysis.
Liu L; Ahmed T; Petty WJ; Grant S; Ruiz J; Lycan TW; Topaloglu U; Chou PC; Miller LD; Hawkins GA; Alexander-Miller MA; O'Neill SS; Powell BL; D'Agostino RB; Munden RF; Pasche B; Zhang W
Mol Oncol; 2021 Feb; 15(2):462-472. PubMed ID: 33107184
[TBL] [Abstract][Full Text] [Related]
9. YTHDF1 Promotes Cyclin B1 Translation through m
Lou X; Ning J; Liu W; Li K; Qian B; Xu D; Wu Y; Zhang D; Cui W
Cells; 2021 Jul; 10(7):. PubMed ID: 34359836
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma.
Nokin MJ; Darbo E; Travert C; Drogat B; Lacouture A; San José S; Cabrera N; Turcq B; Prouzet-Mauleon V; Falcone M; Villanueva A; Wang H; Herfs M; Mosteiro M; Jänne PA; Pujol JL; Maraver A; Barbacid M; Nadal E; Santamaría D; Ambrogio C
JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32759499
[TBL] [Abstract][Full Text] [Related]
11. The level of oncogenic Ras determines the malignant transformation of Lkb1 mutant tissue in vivo.
Rackley B; Seong CS; Kiely E; Parker RE; Rupji M; Dwivedi B; Heddleston JM; Giang W; Anthony N; Chew TL; Gilbert-Ross M
Commun Biol; 2021 Jan; 4(1):142. PubMed ID: 33514834
[TBL] [Abstract][Full Text] [Related]
12. Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma.
Hu K; Li K; Lv J; Feng J; Chen J; Wu H; Cheng F; Jiang W; Wang J; Pei H; Chiao PJ; Cai Z; Chen Y; Liu M; Pang X
J Clin Invest; 2020 Apr; 130(4):1752-1766. PubMed ID: 31874110
[TBL] [Abstract][Full Text] [Related]
13. KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS.
Ambrogio C; Köhler J; Zhou ZW; Wang H; Paranal R; Li J; Capelletti M; Caffarra C; Li S; Lv Q; Gondi S; Hunter JC; Lu J; Chiarle R; Santamaría D; Westover KD; Jänne PA
Cell; 2018 Feb; 172(4):857-868.e15. PubMed ID: 29336889
[TBL] [Abstract][Full Text] [Related]
14. Inhibitor of Differentiation-1 Sustains Mutant
Román M; López I; Guruceaga E; Baraibar I; Ecay M; Collantes M; Nadal E; Vallejo A; Cadenas S; Miguel ME; Jang JH; Martin-Uriz PS; Castro-Labrador L; Vilas-Zornoza A; Lara-Astiaso D; Ponz-Sarvise M; Rolfo C; Santos ES; Raez LE; Taverna S; Behrens C; Weder W; Wistuba II; Vicent S; Gil-Bazo I
Cancer Res; 2019 Feb; 79(3):625-638. PubMed ID: 30563891
[TBL] [Abstract][Full Text] [Related]
15. Effects of different KRAS mutants and Ki67 expression on diagnosis and prognosis in lung adenocarcinoma.
Wang J; Dong L; Zheng Z; Zhu Z; Xie B; Xie Y; Li X; Chen B; Li P
Sci Rep; 2024 Feb; 14(1):4085. PubMed ID: 38374309
[TBL] [Abstract][Full Text] [Related]
16. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
Loboda A; Nebozhyn M; Klinghoffer R; Frazier J; Chastain M; Arthur W; Roberts B; Zhang T; Chenard M; Haines B; Andersen J; Nagashima K; Paweletz C; Lynch B; Feldman I; Dai H; Huang P; Watters J
BMC Med Genomics; 2010 Jun; 3():26. PubMed ID: 20591134
[TBL] [Abstract][Full Text] [Related]
17. Near-Complete Response to Combined Pembrolizumab and Platinum-Doublet in a Patient With STK11/KRAS Mutated Advanced Lung Adenocarcinoma.
Pathak R; Salgia R
Clin Lung Cancer; 2022 Mar; 23(2):e137-e139. PubMed ID: 34419376
[No Abstract] [Full Text] [Related]
18. RANKL acts an unfavorable prognostic biomarker and potential target in advanced KRAS-mutated lung adenocarcinoma.
Li HS; Liu CM; Wang Y
Thorac Cancer; 2023 May; 14(15):1368-1382. PubMed ID: 37021520
[TBL] [Abstract][Full Text] [Related]
19. STK11 loss leads to YAP1-mediated transcriptional activation in human KRAS-driven lung adenocarcinoma cell lines.
Lenahan SM; Sarausky HM; Deming P; Seward DJ
Cancer Gene Ther; 2024 Jan; 31(1):1-8. PubMed ID: 37968341
[TBL] [Abstract][Full Text] [Related]
20. mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer.
Liang SQ; Bührer ED; Berezowska S; Marti TM; Xu D; Froment L; Yang H; Hall SRR; Vassella E; Yang Z; Kocher GJ; Amrein MA; Riether C; Ochsenbein AF; Schmid RA; Peng RW
Oncogene; 2019 Jan; 38(5):622-636. PubMed ID: 30171261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
